Report cover image

Global Peptide CDMO Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 194 Pages
SKU # APRC20361039

Description

Summary

According to APO Research, The global Peptide CDMO market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Peptide CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Peptide CDMO include Xinbang Pharma, ScinoPharm, SN Biopharm, Genscript, AmbioPharm, USV Peptides, Thermofischer, PolyPeptide and Piramal Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptide CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Peptide CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide CDMO revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Peptide CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Peptide CDMO revenue, projected growth trends, production technology, application and end-user industry.

Peptide CDMO Segment by Company

Xinbang Pharma
ScinoPharm
SN Biopharm
Genscript
AmbioPharm
USV Peptides
Thermofischer
PolyPeptide
Piramal Pharma
JPT
CPC Scientific
CordenPharma
CBL
Bio Basic
Bachem
Peptide CDMO Segment by Type

APIs and Intermediates
FDF
Peptide CDMO Segment by Application

Commercial
Academic Research
Other
Peptide CDMO Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Peptide CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Peptide CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide CDMO revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Table of Contents

194 Pages
1 Market Overview
1.1 Product Definition
1.2 Peptide CDMO Market by Type
1.2.1 Global Peptide CDMO Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 APIs and Intermediates
1.2.3 FDF
1.3 Peptide CDMO Market by Application
1.3.1 Global Peptide CDMO Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Commercial
1.3.3 Academic Research
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Peptide CDMO Market Dynamics
2.1 Peptide CDMO Industry Trends
2.2 Peptide CDMO Industry Drivers
2.3 Peptide CDMO Industry Opportunities and Challenges
2.4 Peptide CDMO Industry Restraints
3 Global Growth Perspective
3.1 Global Peptide CDMO Market Perspective (2020-2031)
3.2 Global Peptide CDMO Growth Trends by Region
3.2.1 Global Peptide CDMO Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Peptide CDMO Market Size by Region (2020-2025)
3.2.3 Global Peptide CDMO Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Peptide CDMO Revenue by Players
4.1.1 Global Peptide CDMO Revenue by Players (2020-2025)
4.1.2 Global Peptide CDMO Revenue Market Share by Players (2020-2025)
4.1.3 Global Peptide CDMO Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Peptide CDMO Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Peptide CDMO Key Players Headquarters & Area Served
4.4 Global Peptide CDMO Players, Product Type & Application
4.5 Global Peptide CDMO Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Peptide CDMO Market CR5 and HHI
4.6.3 2024 Peptide CDMO Tier 1, Tier 2, and Tier 3
5 Peptide CDMO Market Size by Type
5.1 Global Peptide CDMO Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Peptide CDMO Revenue by Type (2020-2031)
5.3 Global Peptide CDMO Revenue Market Share by Type (2020-2031)
6 Peptide CDMO Market Size by Application
6.1 Global Peptide CDMO Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Peptide CDMO Revenue by Application (2020-2031)
6.3 Global Peptide CDMO Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Xinbang Pharma
7.1.1 Xinbang Pharma Comapny Information
7.1.2 Xinbang Pharma Business Overview
7.1.3 Xinbang Pharma Peptide CDMO Revenue and Gross Margin (2020-2025)
7.1.4 Xinbang Pharma Peptide CDMO Product Portfolio
7.1.5 Xinbang Pharma Recent Developments
7.2 ScinoPharm
7.2.1 ScinoPharm Comapny Information
7.2.2 ScinoPharm Business Overview
7.2.3 ScinoPharm Peptide CDMO Revenue and Gross Margin (2020-2025)
7.2.4 ScinoPharm Peptide CDMO Product Portfolio
7.2.5 ScinoPharm Recent Developments
7.3 SN Biopharm
7.3.1 SN Biopharm Comapny Information
7.3.2 SN Biopharm Business Overview
7.3.3 SN Biopharm Peptide CDMO Revenue and Gross Margin (2020-2025)
7.3.4 SN Biopharm Peptide CDMO Product Portfolio
7.3.5 SN Biopharm Recent Developments
7.4 Genscript
7.4.1 Genscript Comapny Information
7.4.2 Genscript Business Overview
7.4.3 Genscript Peptide CDMO Revenue and Gross Margin (2020-2025)
7.4.4 Genscript Peptide CDMO Product Portfolio
7.4.5 Genscript Recent Developments
7.5 AmbioPharm
7.5.1 AmbioPharm Comapny Information
7.5.2 AmbioPharm Business Overview
7.5.3 AmbioPharm Peptide CDMO Revenue and Gross Margin (2020-2025)
7.5.4 AmbioPharm Peptide CDMO Product Portfolio
7.5.5 AmbioPharm Recent Developments
7.6 USV Peptides
7.6.1 USV Peptides Comapny Information
7.6.2 USV Peptides Business Overview
7.6.3 USV Peptides Peptide CDMO Revenue and Gross Margin (2020-2025)
7.6.4 USV Peptides Peptide CDMO Product Portfolio
7.6.5 USV Peptides Recent Developments
7.7 Thermofischer
7.7.1 Thermofischer Comapny Information
7.7.2 Thermofischer Business Overview
7.7.3 Thermofischer Peptide CDMO Revenue and Gross Margin (2020-2025)
7.7.4 Thermofischer Peptide CDMO Product Portfolio
7.7.5 Thermofischer Recent Developments
7.8 PolyPeptide
7.8.1 PolyPeptide Comapny Information
7.8.2 PolyPeptide Business Overview
7.8.3 PolyPeptide Peptide CDMO Revenue and Gross Margin (2020-2025)
7.8.4 PolyPeptide Peptide CDMO Product Portfolio
7.8.5 PolyPeptide Recent Developments
7.9 Piramal Pharma
7.9.1 Piramal Pharma Comapny Information
7.9.2 Piramal Pharma Business Overview
7.9.3 Piramal Pharma Peptide CDMO Revenue and Gross Margin (2020-2025)
7.9.4 Piramal Pharma Peptide CDMO Product Portfolio
7.9.5 Piramal Pharma Recent Developments
7.10 JPT
7.10.1 JPT Comapny Information
7.10.2 JPT Business Overview
7.10.3 JPT Peptide CDMO Revenue and Gross Margin (2020-2025)
7.10.4 JPT Peptide CDMO Product Portfolio
7.10.5 JPT Recent Developments
7.11 CPC Scientific
7.11.1 CPC Scientific Comapny Information
7.11.2 CPC Scientific Business Overview
7.11.3 CPC Scientific Peptide CDMO Revenue and Gross Margin (2020-2025)
7.11.4 CPC Scientific Peptide CDMO Product Portfolio
7.11.5 CPC Scientific Recent Developments
7.12 CordenPharma
7.12.1 CordenPharma Comapny Information
7.12.2 CordenPharma Business Overview
7.12.3 CordenPharma Peptide CDMO Revenue and Gross Margin (2020-2025)
7.12.4 CordenPharma Peptide CDMO Product Portfolio
7.12.5 CordenPharma Recent Developments
7.13 CBL
7.13.1 CBL Comapny Information
7.13.2 CBL Business Overview
7.13.3 CBL Peptide CDMO Revenue and Gross Margin (2020-2025)
7.13.4 CBL Peptide CDMO Product Portfolio
7.13.5 CBL Recent Developments
7.14 Bio Basic
7.14.1 Bio Basic Comapny Information
7.14.2 Bio Basic Business Overview
7.14.3 Bio Basic Peptide CDMO Revenue and Gross Margin (2020-2025)
7.14.4 Bio Basic Peptide CDMO Product Portfolio
7.14.5 Bio Basic Recent Developments
7.15 Bachem
7.15.1 Bachem Comapny Information
7.15.2 Bachem Business Overview
7.15.3 Bachem Peptide CDMO Revenue and Gross Margin (2020-2025)
7.15.4 Bachem Peptide CDMO Product Portfolio
7.15.5 Bachem Recent Developments
8 North America
8.1 North America Peptide CDMO Revenue (2020-2031)
8.2 North America Peptide CDMO Revenue by Type (2020-2031)
8.2.1 North America Peptide CDMO Revenue by Type (2020-2025)
8.2.2 North America Peptide CDMO Revenue by Type (2026-2031)
8.3 North America Peptide CDMO Revenue Share by Type (2020-2031)
8.4 North America Peptide CDMO Revenue by Application (2020-2031)
8.4.1 North America Peptide CDMO Revenue by Application (2020-2025)
8.4.2 North America Peptide CDMO Revenue by Application (2026-2031)
8.5 North America Peptide CDMO Revenue Share by Application (2020-2031)
8.6 North America Peptide CDMO Revenue by Country
8.6.1 North America Peptide CDMO Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Peptide CDMO Revenue by Country (2020-2025)
8.6.3 North America Peptide CDMO Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
9 Europe
9.1 Europe Peptide CDMO Revenue (2020-2031)
9.2 Europe Peptide CDMO Revenue by Type (2020-2031)
9.2.1 Europe Peptide CDMO Revenue by Type (2020-2025)
9.2.2 Europe Peptide CDMO Revenue by Type (2026-2031)
9.3 Europe Peptide CDMO Revenue Share by Type (2020-2031)
9.4 Europe Peptide CDMO Revenue by Application (2020-2031)
9.4.1 Europe Peptide CDMO Revenue by Application (2020-2025)
9.4.2 Europe Peptide CDMO Revenue by Application (2026-2031)
9.5 Europe Peptide CDMO Revenue Share by Application (2020-2031)
9.6 Europe Peptide CDMO Revenue by Country
9.6.1 Europe Peptide CDMO Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Peptide CDMO Revenue by Country (2020-2025)
9.6.3 Europe Peptide CDMO Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Netherlands
9.6.9 Nordic Countries
10 China
10.1 China Peptide CDMO Revenue (2020-2031)
10.2 China Peptide CDMO Revenue by Type (2020-2031)
10.2.1 China Peptide CDMO Revenue by Type (2020-2025)
10.2.2 China Peptide CDMO Revenue by Type (2026-2031)
10.3 China Peptide CDMO Revenue Share by Type (2020-2031)
10.4 China Peptide CDMO Revenue by Application (2020-2031)
10.4.1 China Peptide CDMO Revenue by Application (2020-2025)
10.4.2 China Peptide CDMO Revenue by Application (2026-2031)
10.5 China Peptide CDMO Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Peptide CDMO Revenue (2020-2031)
11.2 Asia Peptide CDMO Revenue by Type (2020-2031)
11.2.1 Asia Peptide CDMO Revenue by Type (2020-2025)
11.2.2 Asia Peptide CDMO Revenue by Type (2026-2031)
11.3 Asia Peptide CDMO Revenue Share by Type (2020-2031)
11.4 Asia Peptide CDMO Revenue by Application (2020-2031)
11.4.1 Asia Peptide CDMO Revenue by Application (2020-2025)
11.4.2 Asia Peptide CDMO Revenue by Application (2026-2031)
11.5 Asia Peptide CDMO Revenue Share by Application (2020-2031)
11.6 Asia Peptide CDMO Revenue by Country
11.6.1 Asia Peptide CDMO Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Peptide CDMO Revenue by Country (2020-2025)
11.6.3 Asia Peptide CDMO Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Peptide CDMO Revenue (2020-2031)
12.2 SAMEA Peptide CDMO Revenue by Type (2020-2031)
12.2.1 SAMEA Peptide CDMO Revenue by Type (2020-2025)
12.2.2 SAMEA Peptide CDMO Revenue by Type (2026-2031)
12.3 SAMEA Peptide CDMO Revenue Share by Type (2020-2031)
12.4 SAMEA Peptide CDMO Revenue by Application (2020-2031)
12.4.1 SAMEA Peptide CDMO Revenue by Application (2020-2025)
12.4.2 SAMEA Peptide CDMO Revenue by Application (2026-2031)
12.5 SAMEA Peptide CDMO Revenue Share by Application (2020-2031)
12.6 SAMEA Peptide CDMO Revenue by Country
12.6.1 SAMEA Peptide CDMO Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Peptide CDMO Revenue by Country (2020-2025)
12.6.3 SAMEA Peptide CDMO Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.